<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03548480</url>
  </required_header>
  <id_info>
    <org_study_id>FSJD-BALPWS-2018</org_study_id>
    <nct_id>NCT03548480</nct_id>
  </id_info>
  <brief_title>Targeting the Gut Microbiome for Prader-Willi Syndrome Treatment</brief_title>
  <acronym>BALPWS</acronym>
  <official_title>Targeting the Gut Microbiome for Prader-Willi Syndrome Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Sant Joan de Déu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Sant Joan de Déu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The gut microbiome has recently emerged as a major contributor to obesity, systemic&#xD;
      inflammation, and metabolic disease. Furthermore, intestinal bacteria are crucial players in&#xD;
      the gut-brain axis, regulating a broad range of central nervous system processes, from&#xD;
      satiety mechanisms to anxiety and social behavior. Thus, targeting the microbiome is being&#xD;
      actively investigated as a therapeutic strategy for a wide array of diseases, including&#xD;
      obesity, anxiety, depression, and autism. Among all intestinal bacteria, Bifidobacterium&#xD;
      animalis spp. lactis (BAL) has shown promise for obesity treatment in experimental animal&#xD;
      models and human subjects, improving body composition and metabolic health, and reducing&#xD;
      energy intake. Moreover, tryptophan metabolism, a crucial regulator of satiety mechanisms and&#xD;
      anxiety, is a main target of BAL. Given that clinical manifestations of Prader-Willi syndrome&#xD;
      (PWS) include hyperphagia, anxiety, altered body composition, and metabolic dysregulation,&#xD;
      the aforementioned effects of BAL might prove highly beneficial for children with PWS. Here,&#xD;
      the investigators will test this hypothesis by performing a randomized double-blinded&#xD;
      placebo-controlled crossover clinical study to assess the effects of BAL supplementation on&#xD;
      an array of clinical manifestations of PWS. Children with PWS will undergo a 3-month&#xD;
      placebo/probiotic treatment period, a 3-month washout period, followed by a 3-month&#xD;
      probiotic/placebo supplementation. Anthropometric, biochemical, and psychological data as&#xD;
      well as biological samples will be obtained at the beginning of the study, and after each of&#xD;
      the study periods, with a total of four time-points. Specifically, the investigators will&#xD;
      determine body composition by DXA analysis; metabolic health by assessing glucose and lipid&#xD;
      metabolic parameters as well as circulating hormonal and cytokine levels; thermoregulation by&#xD;
      non-invasive thermal imaging; and hyperphagia and emotional and behavioral problems by&#xD;
      applying parental-rated validated questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in percent body fat</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by DXA scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lipid profile (triglyceride, cholesterol)</measure>
    <time_frame>3 months</time_frame>
    <description>Blood test after overnight fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose metabolic parameters (glucose, insulin, HbA1c)</measure>
    <time_frame>3 months</time_frame>
    <description>Blood test after overnight fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating cytokine levels</measure>
    <time_frame>3 months</time_frame>
    <description>Quantified in plasma samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hyperphagia</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by validated questionnaire (HQ-CT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in thermoregulation</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by thermal imaging</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in plasma metabolome</measure>
    <time_frame>3 months</time_frame>
    <description>Liquid chromatography coupled to mass spectrometry will be used to obtain a comprehensive metabolic profile of plasma samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in urine metabolome</measure>
    <time_frame>3 months</time_frame>
    <description>Liquid chromatography coupled to mass spectrometry will be used to obtain a comprehensive metabolic profile of urine samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in intestinal microbiome</measure>
    <time_frame>3 months</time_frame>
    <description>DNA isolated from fecal samples will be analyzed by sequencing.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intervention with a daily dose of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Intervention with a daily dose of probiotic</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with Prader-Willi Syndrome with genetic confirmation&#xD;
&#xD;
          -  On a stable diet and medication regimen for at least the last two months before&#xD;
             enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current enrollment in or discontinuation within the last 30 days from a clinical trial&#xD;
&#xD;
          -  Presence of other medical problems that would preclude study participation&#xD;
&#xD;
          -  Patients with a history of bariatric surgery&#xD;
&#xD;
          -  Unsuitable for inclusion in the study in the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carles Lerin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Sant Joan de Déu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

